# data[].attributes.attachment_link.readable_text
The next generation Evolut TM PRO+ transcatheter aortic valve system provides industry-leading hemodynamics - allowing your patients to return to activity faster. 1,2,3

DOWNLOAD BROCHURE

Meet the Evolut PRO+ SYSTEM

With a design built on the proven Evolut platform, the Evolut PRO+ system features:

Lowest delivery profile
for access down to 5.0 mm vessels with the 23-29 mm valves.

Advanced sealing
for all valve sizes with the addition of the external tissue wrap to the 34 mm valve.

EXCEPTIONAL DESIGN

Today, the Evolut PRO+ valve design means no tradeoffs.

It provides the lowest delivery profile and added surface area contact between the valve and the native aortic annulus to further advance valve sealing performance.

In addition, our exceptional valve design is taking patient outcomes above and beyond - contributing to our industry-leading hemodynamics.

TREAT MORE PATIENTS

The Evolut PRO+ system is the only TAVR platform indicated to treat annulus ranges up to 30 mm diameter and has the ability to treat the broadest annulus range* of any commercially available TAVR system.

CONTROL DURING DEPLOYMENT

The Evolut PRO+ delivery system:

Assists in accurate positioning of the valve

Features a 1:1 response for immediate feedback between the deployment knob and the movement of the capsule

Provides you the option to recapture and reposition⁴ for more accurate placement

MANUALS AND TECHNICAL GUIDES

Access instructions for use and other technical manuals in the Medtronic Manual Library. Search by the product name (e.g., Evolut) or model number. You may also call 800-961-9055 for a copy of a manual.

EVOLUT PRO+ PLATFORM RESOURCES

RESOURCES

Find additional feature information, educational resources, and tools.

*

Broadest annulus range based on CT derived diameters.

†

Measurement is for TAV-in-SAV only.

¹

Bleiziffer S, Eichinger WB, Hettich I, et al. Impact of patient-prosthesis mismatch on exercise capacity in patients after bioprosthesis aortic valve replacement. Heart. May 2008;94(5):637-641.

²

van Slooten YJ, van Melle JP, Freling HG, et al. Aortic valve prosthesis-patient mismatch and exercise capacity in adult patients with congenital heart disease. Heart. January 2016;102(2):107-113.

³

Pibarot P, Dumesnil JG, Jobin J, Cartier P, Honos G, Durand LG. Hemodynamic and physical performance during maximal exercise in patients with an aortic bioprosthetic valve: comparison of stentless versus stented bioprostheses. J Am Coll Cardiol. November 1, 1999;34(5):1609-1617.

⁴

Up to 80% deployment. The valve can be partially or fully recaptured up to three times prior to the point of no recapture. Third attempt must be a complete recapture and retrieval from patient.

# data[].attributes.attachment_link.description
The next generation Evolut TM PRO+ transcatheter aortic valve system provides industry-leading hemodynamics - allowing your patients to return to activity faster. 1,2,3 DOWNLOAD BROCHURE Meet the Evolut PRO+ SYSTEM With a design built on the proven Evolut platform, the Evolut PRO+ system features: Lowest delivery profile for access down to 5.0 mm vessels with the 23-29 mm valves.

# data[].attributes.body
Medtronic. 2019. Above and beyond: Evolut pro+ transcatheter aortic valve system [Brochure].

Randall, M. H., & Bavry, A. A. (2020). Update on Transcatheter Aortic Valve Replacement. Cardiology and therapy, 9(1), 75–84. https://doi.org/10.1007/s40119-020-00167-6

U.S. Food and Drug Administration. (2019, August 16). Medtronic corevalve evolut r system and medtronic corevalve evolut pro system - P130021/S058. https://www.fda.gov/medical-devices/recently-approved-devices/medtronic-corevalve-evolut-r-system-and-medtronic-corevalve-evolut-pro-system-p130021s058

# data[].attributes.body
The Evolut Pro+ system is a large contributing factor to the advancement of treatment of aortic stenosis. Replacing the valve in a less invasive way provides patients with options for treatment. In my opinion, it is important that providers present patients with all the options for treatment and rely on the patient's preference in the decision making process regarding the type of valve replacement. The pro of shorter time of recovery translates to a shorter interruption of daily life and a quicker return to an active lifestyle, and in my opinion is worth the risk for potential pacemaker implantation. While the TAVR is much more expensive than SAVR, the anesthesia time and length of stay is significantly less, and can lead to decreased cost associated with the impatient stay. If it were my heart, I would chose the current innovation of TAVR with the Evolut Pro+ system.

# data[].attributes.body
Sources supporting the current innovation are the U.S. Food and Drug Administration, a published journal article, and the valve manufacturer, Medtronic. Publication dates range from 2019-2020.

# data[].attributes.body
Correct aortic valve stenosis without traditional sternotomy

Advanced sealing around the valve annulus to prevent post-operative aortic insufficiency

Lowest delivery profile to allow delivery through smaller sized vessels

Option to recapture the valve for repositioning

Shorter time of recovery and hospitalization compared to surgical valve replacement (SAVR)

# data[].attributes.body
Higher rates of atrioventricular blocks requiring pacemaker compared to SAVR

Cost of TAVR ($33,000) compared to SAVR ($3,500)

Risk of vascular complication at the site of implant

# data[].attributes.body
"Transcatheter aortic valve replacement (TAVR) is a minimally invasive approach to treat patients diagnosed with symptomatic severe aortic stenosis" (Randall & Bavry, 2020). The TAVR has been offered as an alternative to traditional aortic valve replacement since 2002, with indications expanding to now include all categories of surgical risk stratification (U.S. Food and Drug Administration, 2019). As of August 2019, the newest technology in transcatheter valve therapy approved by the U.S. Food and Drug Administration is Medtronic's Evolut Pro+ system (2019). The Evolut Pro+ is built on the unique design of the supra-annular, self-expanding valve, with the addition of a porcine pericardial tissue wrap to treat the broadest range of valve annulus sizes (Randall & Bavry, 2020). Once the Evolut Pro+ is implanted, patients experience single digit aortic valve mean gradients, increased blood flow, and achieving improved quality of life (Medtronic, 2019, pp. 4-5). The current innovation in TAVR valve design is a valuable treatment or aortic stenosis.

# data[].attributes.body
Bringing the Evolut Pro+ system to our facility's structural heart program would allow our patients the most up-to-date technology, allowing us to better serve those diagnosed with severe aortic stenosis in our community. Below is a list of members on the TAVR Task Force Committee, and the strengths they each bring to the group.
Alice the achiever - Alice is our group leader, and will report out information on our innovation to facility leadership. She is a fearless, productive team member who will go above and beyond to make sure our committee is successful.
Disciplined Daniel - Daniel will ensure that our overall goal of implementing the Evolut Pro+ is achieved in a systematic, streamlined way. He will ensure our meeting objectives are covered thoroughly.
Rose the relator - Rose is well known and friendly, and also involved on other committees in the facility. She will be a great resource in identifying any key stakeholders and ensuring our committee is well supported.
Abraham the arranger - Abraham will assist in scheduling our committee meetings, and keep record of our minutes, progress, and on-going projects. He will make sure the group stay organized to meet our end goal.
Louis the learner - Louis brings the excitement and passion for the current innovation. He is eager to learn and share why the Evolut Pro+ is worth the investment, and will continuously challenge our committee to seek the best technology for our patients.
The TAVR Task Force Committee is composed of talented individuals who have a meaningful strength or balance our group.